公开(公告)号：EP1272185B1

公开(公告)日：2005-07-27

申请号：EP01907938.3

申请日：2001-03-01

申请人： AstraZeneca AB

发明人： HENNEQUIN, Laurent François André ,  CRAWLEY, Graham Charles ,  MCKERRECHER, Darren ,  PLE, Patrick ,  POYSER, Jeffrey Philip ,  LAMBERT, Christine Marie Paul

IPC分类号： A61K31/505 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  C07D487/04

CPC分类号： A61K31/519 ,  A61K31/517 ,  A61K31/5377

公开(公告)号：EP1272185A2

公开(公告)日：2003-01-08

申请号：EP01907938.3

申请日：2001-03-01

申请人： AstraZeneca AB

发明人： HENNEQUIN, Laurent François André ,  CRAWLEY, Graham Charles ,  MCKERRECHER, Darren ,  PLE, Patrick ,  POYSER, Jeffrey Philip ,  LAMBERT, Christine Marie Paul

IPC分类号： A61K31/505 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  C07D487/04

CPC分类号： A61K31/519 ,  A61K31/517 ,  A61K31/5377

摘要： The invention concerns the use of a quinazoline derivative of Formula (I) wherein Q1 includes a quinazoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q3-X1- wherein X1 includes a direct bond and O and Q3 includes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl; each of R?2 and R3¿ is hydrogen or (1-6C)alkyl; Z includes O, S and NH; and Q2 includes aryl and aryl-(1-3C)alkyl or a pharmaceutically-acceptable salt thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human.